Also from this source

10 May, 2017, 06:45 ET Merrimack Announces Management Change


You just read:

Merrimack Announces Inclusion of ONIVYDE® (irinotecan liposome injection) as a Category 1 Treatment Option in the 2016 NCCN Guidelines for Pancreatic Adenocarcinoma

News provided by

Merrimack Pharmaceuticals, Inc.

24 Mar, 2016, 07:00 ET